Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 5/20 | 0.37 |
| ▸ | GUCY1A2 | P33402 | 5/20 | 0.37 |
| ▸ | GUCY1A1 | Q02108 | 5/20 | 0.37 |
| ▸ | GUCY1B1 | Q02153 | 5/20 | 0.37 |
| ▸ | F2 | P00734 | 4/20 | 0.34 |
| ▸ | JAK3 | P52333 | 5/20 | 0.33 |
| ▸ | JAK2 | O60674 | 3/20 | 0.33 |
| ▸ | AADAT | Q8N5Z0 | 4/20 | 0.33 |
| ▸ | JAK1 | P23458 | 3/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10044716 | 0.94 | GUCY1B2 (0.38) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1F2 | |
| SCHEMBL10044774 | 0.90 | GUCY1B2 (0.40) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1F2 | |
| SCHEMBL10044742 | 0.87 | GUCY1B2 (0.38) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1F2 | |
| SCHEMBL10044737 | 0.87 | GUCY1B2 (0.37) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1JAK3 | |
| SCHEMBL10044711 | 0.86 | GUCY1B2 (0.37) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1F2 | |
| SCHEMBL10044744 | 0.86 | GUCY1B2 (0.37) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1F2 | |
| SCHEMBL10072309 | 0.85 | F2 (0.36) | F2JAK3JAK2AADATJAK1 | |
| SCHEMBL10044734 | 0.83 | AADAT (0.45) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1AADAT | |
| SCHEMBL10044766 | 0.83 | GUCY1B2 (0.38) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1JAK3 | |
| SCHEMBL13305968 | 0.79 | GUCY1B2 (0.40) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1AADAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221336-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221336-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-20120157429-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2012-06-21 | — | — | US | disclosed |
| US-20120157429-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2012-06-21 | — | — | US | disclosed |
| US-20100160287-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160287-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157429-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | JAK2, JAK1, JAK3 | GUCY1B2 2434/4885GUCY1A2 2764/4885GUCY1A1 2301/4885 |
| US-20100160287-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | JAK2, JAK1, JAK3 | GUCY1B2 2434/4885GUCY1A2 2764/4885GUCY1A1 2301/4885 |
| US-20140221336-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | JAK2, JAK1, JAK3 | GUCY1B2 2434/4885GUCY1A2 2764/4885GUCY1A1 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.